AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ORIC Pharmaceuticals Presents Phase 1b Trial Data for Enozertinib at ESMO Asia Congress 2025
ByAinvest
Thursday, Dec 4, 2025 10:52 pm ET1min read
ORIC Pharmaceuticals has announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. The data showed positive results in previously treated NSCLC patients with EGFR atypical mutations. Preliminary data in 1L NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations were also disclosed.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet